Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Enobosarm

QUALITY

Veru Inc · Phase 2 · Completed · Enrollment 168

NCT06282458

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Semaglutide and Enobosarm 3 mg QD by mouth (E3G) dailyn/rn/rn/rn/r
Semaglutide and Enobosarm 6 mg QD by mouth (E6G) dailyn/rn/rn/rn/r
GLP-1 receptor agonist and Placebo QD by mouth (PG) dailyn/rn/rn/rn/r

Not shown

  • Semaglutide and Enobosarm 3 mg QD by mouth (E3G) daily: endpoint not reported
  • Semaglutide and Enobosarm 6 mg QD by mouth (E6G) daily: endpoint not reported
  • GLP-1 receptor agonist and Placebo QD by mouth (PG) daily: endpoint not reported